Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
出版年份 2023 全文链接
标题
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
作者
关键词
-
出版物
CANCER CELL
Volume 41, Issue 9, Pages 1551-1566
出版商
Elsevier BV
发表日期
2023-08-17
DOI
10.1016/j.ccell.2023.07.011
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
- (2023) J.M. Versluis et al. ANNALS OF ONCOLOGY
- The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability–high (dMMR/MSI-H) localized and oligometastatic colon cancer: Data from the real world.
- (2023) Sakti Chakrabarti et al. JOURNAL OF CLINICAL ONCOLOGY
- INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).
- (2023) Filippo Pietrantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
- (2023) Kaysia Ludford et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
- (2023) Silvia Novello et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistent mutation burden drives sustained anti-tumor immune responses
- (2023) Noushin Niknafs et al. NATURE MEDICINE
- Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
- (2023) Song Li et al. Nature Communications
- RECISTv1.1 progression in oncology: Shades of gray
- (2023) Brian Topp et al. CANCER CELL
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
- (2023) Samuel Rosner et al. CLINICAL CANCER RESEARCH
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
- (2023) Marina C. Garassino et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
- (2023) Denise M. Wolf et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
- (2023) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
- (2023) Tina Cascone et al. NATURE MEDICINE
- Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
- (2023) Assaf Magen et al. NATURE MEDICINE
- Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
- (2023) Minke W. Lucas et al. Nature Reviews Clinical Oncology
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- (2023) Sapna P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
- (2023) Junjie Hu et al. Genome Medicine
- Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
- (2023) Greta Alì et al. Frontiers in Oncology
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- (2023) Mariano Provencio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung tumor–infiltrating T reg have divergent transcriptional profiles and function linked to checkpoint blockade response
- (2023) Arbor G. Dykema et al. Science Immunology
- Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
- (2022) L. Gianni et al. ANNALS OF ONCOLOGY
- PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer
- (2022) Julia E. Douglas et al. BMC CANCER
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2022) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- (2022) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
- (2022) Kenneth L. Kehl et al. JAMA Oncology
- Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
- (2022) Ahmed Omar Kaseb et al. Lancet Gastroenterology & Hepatology
- Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
- (2022) Thomas U Marron et al. Lancet Gastroenterology & Hepatology
- Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
- (2022) S. Loibl et al. ANNALS OF ONCOLOGY
- Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
- (2022) Adrienne M. Luoma et al. CELL
- Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.
- (2022) Mariano Provencio-Pulla et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
- (2022) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
- (2022) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
- (2022) Mariano Provencio et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
- (2022) Priyanka Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).
- (2022) Kari Lynn Kendra et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- (2022) Irene L. M. Reijers et al. NATURE MEDICINE
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer
- (2022) Anne-Gaelle Goubet et al. Cancer Discovery
- Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
- (2022) Xuan Zhang et al. Frontiers in Immunology
- LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
- (2022) M. Chalabi et al. ANNALS OF ONCOLOGY
- Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
- (2022) Keyu Li et al. CANCER CELL
- Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study
- (2022) Qiao-Xuan Wang et al. EUROPEAN JOURNAL OF CANCER
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227
- (2022) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant relatlimab and nivolumab in resectable melanoma
- (2022) Rodabe N. Amaria et al. NATURE
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
- (2022) Neil D. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
- (2022) Wu-tong Ju et al. Nature Communications
- Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer
- (2022) Xiaohuan Tang et al. OncoImmunology
- Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
- (2022) Fabio Conforti et al. JAMA Oncology
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
- (2021) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
- (2021) Rom Leidner et al. Journal for ImmunoTherapy of Cancer
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
- (2021) Lajos Pusztai et al. CANCER CELL
- Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
- (2021) Renata Ferrarotto et al. CLINICAL CANCER RESEARCH
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
- (2021) Justina X. Caushi et al. NATURE
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
- (2021) Huabin Hu et al. Lancet Gastroenterology & Hepatology
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Mismatch Repair Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
- (2020) Andrea Cercek et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
- (2020) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
- (2020) Joshua E Reuss et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
- (2019) Rodabe N Amaria et al. LANCET ONCOLOGY
- Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
- (2019) Jiajia Zhang et al. CLINICAL CANCER RESEARCH
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials
- (2010) Wei-An Song et al. Journal of Thoracic Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now